Ocrelizumab (OCREVUS™), an anti-B cell therapy has been approved by the FDA as of March 28th 2017, for the treatment of Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This treatment is highly effective for RRMS, based on the data from the Phase III clinical studies. It is also the first drug approved for use in PPMS. At IMSMP/TISCH we have used Rituximab, a similar anti-B cell treatment, for the past 16 years with great success. It is because...
more- Services
- Team
- Patient Education
- Diagnosing MS
- Understanding Some Basics About MS
- Relapsing Remitting MS
- Secondary Progressive MS
- Primary Progressive MS
- Preparing for Your New Patient Visit
- Preparing for a Spinal Tap
- Injection & Medication Counseling
- Relapse vs. Pseudorelapse
- Neuromyelitis Optics vs. Multiple Sclerosis
- Resources
- FAQ
- Research
- News
- Contact
- Leave a Review